Education
About Us
Working with TipRanks
Follow Us
Calidi Biotherapeutics (CLDI)
:CLDI
Total Valuation
Calidi Biotherapeutics has a market cap or net worth of $8.96M. The enterprise value is $6.88M.
Market Cap$8.96M
Enterprise Value$6.88M
Share Statistics
Calidi Biotherapeutics has 7,167,721 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding7,167,721
Owned by Insiders4.94%
Owned by Institutions0.82%
Financial Efficiency
Calidi Biotherapeutics’s return on equity (ROE) is -14.43 and return on invested capital (ROIC) is -238.61%.
Return on Equity (ROE)-14.43
Return on Assets (ROA)-1.56
Return on Invested Capital (ROIC)-238.61%
Return on Capital Employed (ROCE)-4.65
Revenue Per Employee0.00
Profits Per Employee-793.18K
Employee Count28
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Calidi Biotherapeutics is ―. Calidi Biotherapeutics’s PEG ratio is 0.00500.
PE Ratio―
PS Ratio0.00
PB Ratio5.98
Price to Fair Value5.98
Price to FCF-0.47
Price to Operating Cash Flow-0.34
PEG Ratio0.00500
Income Statement
In the last 12 months, Calidi Biotherapeutics had revenue of 0.00 and earned -22.14M in profits. Earnings per share was -35.70.
Revenue0.00
Gross Profit0.00
Operating Income-21.78M
Pretax Income-22.20M
Net Income-22.14M
EBITDA-19.73M
Earnings Per Share (EPS)-35.70
Cash Flow
In the last 12 months, operating cash flow was -21.67M and capital expenditures -96.00K, giving a free cash flow of -21.77M billion.
Operating Cash Flow-21.67M
Free Cash Flow-21.77M
Free Cash Flow per Share-3.04
Dividends & Yields
Calidi Biotherapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.70
52-Week Price Change-91.67%
50-Day Moving Average1.49
200-Day Moving Average4.11
Relative Strength Index (RSI)39.54
Average Volume (3m)164.15K
Important Dates
Calidi Biotherapeutics upcoming earnings date is Mar 13, 2026, After Close (Confirmed).
Last Earnings DateNov 13, 2025
Next Earnings DateMar 13, 2026
Ex-Dividend Date―
Financial Position
Calidi Biotherapeutics as a current ratio of 1.08, with Debt / Equity ratio of 45.00%
Current Ratio1.08
Quick Ratio1.08
Debt to Market Cap0.41
Net Debt to EBITDA0.12
Interest Coverage Ratio-23.34
Taxes
In the past 12 months, Calidi Biotherapeutics has paid 14.00K in taxes.
Income Tax14.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Calidi Biotherapeutics EV to EBITDA ratio is -0.32, with an EV/FCF ratio of -0.34.
EV to Sales0.00
EV to EBITDA-0.32
EV to Free Cash Flow-0.34
EV to Operating Cash Flow-0.34
Balance Sheet
Calidi Biotherapeutics has $10.38M in cash and marketable securities with $3.11M in debt, giving a net cash position of $7.26M billion.
Cash & Marketable Securities$10.38M
Total Debt$3.11M
Net Cash$7.26M
Net Cash Per Share$1.01
Tangible Book Value Per Share$2.96
Margins
Gross margin is -3.26%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin-3.26%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Calidi Biotherapeutics is ―, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target―
Price Target Upside―
Analyst ConsensusModerate Buy
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast87.42%